Fundraising Fox
Atavistik Bio
Founded 2021 · 40 employees on LinkedIn · 4 known investors
Find your way into Atavistik Bio
Sign up to see every warm intro you have to Atavistik Bio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Atavistik Bio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Atavistik Bio develops selective allosteric therapeutics using a proprietary discovery platform designed to identify functional pockets across multiple protein classes, with an internal focus on rare hematology. The company is advancing multiple drug programs toward regulatory approval and clinical applications for patients with significant unmet medical needs.
Founders & leadership
Investors · 4
How we know: Lux Capital's portfolio page · the company's own site · a partner's Signal profile · funding news · Not right? Tell us
How we know: RA Capital's portfolio page · the company's own site · Not right? Tell us
How we know: The Column Group's portfolio page · the company's own site · a partner's Signal profile · funding news · the VCSheet dataset · Not right? Tell us
How we know: Nextech Invest's portfolio page · a partner's Signal profile · funding news · open dataset · 5k.vc investor directory · Not right? Tell us
Funding
SEC filings, press & company announcements$120M disclosed across 1 of 3 rounds · 2023–2026
- Undisclosed amountSeries B ExtensionMar 2026Source ↗
- $120MSeries B FinancingDec 2025 · 2 sourcesSource ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Atavistik Bio do?
- Atavistik Bio develops selective allosteric therapeutics using a proprietary discovery platform designed to identify functional pockets across multiple protein classes, with an internal focus on rare hematology. The company is advancing multiple drug programs toward regulatory approval and clinical applications for patients with significant unmet medical needs.
- Who are Atavistik Bio's investors?
- Atavistik Bio's investors include Lux Capital, RA Capital, The Column Group, Nextech Invest.
- How much funding has Atavistik Bio raised?
- Atavistik Bio has disclosed $120M raised across 1 of its 3 known rounds.